Table 3.
Pathways enriched by subnetwork modules.
| Module | Gene set | Protein from module | FDR |
|---|---|---|---|
| 0 | Transcriptional regulation of white adipocyte differentiation (R) | 6 | 2.72E − 05 |
| 0 | Chromatin modifying enzymes (R) | 6 | 2.03E − 03 |
| 1 | Mitotic metaphase and anaphase (R) | 23 | 2.00E − 15 |
| 1 | Signaling by Rho GTPases (R) | 21 | 2.00E − 15 |
| 3 | Synthesis of DNA (R) | 11 | 4.44E − 16 |
| 3 | S phase (R) | 11 | 4.44E − 16 |
| 4 | DNA damage bypass (R) | 8 | 9.99E − 16 |
| 4 | Fanconi anemia pathway (N) | 9 | 9.99E − 16 |
| 5 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (P) | 5 | 1.74E − 05 |
| 5 | Wnt signaling pathway (P) | 6 | 2.86E − 05 |
| 6 | Protein kinase a at the centrosome (B) | 2 | 6.92E − 03 |
| 6 | Prostate cancer (K) | 3 | 6.92E − 03 |
| 7 | Signaling by Rho GTPases (R) | 8 | 4.73E − 10 |
| 7 | Regulation of RhoA activity (N) | 2 | 1.07E − 02 |
| 8 | Mitotic telophase/cytokinesis (R) | 4 | 7.08E − 09 |
| 8 | Mitotic prometaphase (R) | 4 | 8.56E − 06 |
| 9 | Interferon alpha/beta signaling (R) | 5 | 6.83E − 09 |
| 9 | ISG15 antiviral mechanism (R) | 4 | 6.35E − 07 |
| 10 | Cadherin signaling pathway (P) | 6 | 4.47E − 09 |
| 10 | Wnt signaling pathway (P) | 6 | 7.94E − 07 |
| 11 | Nucleosome assembly (R) | 9 | 5.55E − 16 |
| 11 | Mitotic prometaphase (R) | 6 | 1.36E − 10 |
| 12 | Beta1 integrin cell surface interactions (N) | 4 | 4.71E − 08 |
| 12 | ECM-receptor interaction (K) | 3 | 2.45E − 05 |
| 13 | Formation of fibrin clot (clotting cascade) (R) | 2 | 1.36E − 02 |
| 13 | AP-1 transcription factor network (N) | 2 | 2.12E − 02 |
| 14 | TGF-beta signaling pathway (P) | 4 | 4.87E − 06 |
| 14 | TGF-beta signaling pathway (K) | 4 | 4.87E − 06 |
| 15 | Insulin-mediated glucose transport (N) | 2 | 9.27E − 03 |
| 15 | Class I PI3K signaling events mediated by Akt (N) | 2 | 9.27E − 03 |
The source of pathway database: C: CellMap, R: Reactome, K: KEGG, N: NCI PID, P: Panther, and B: BioCarta.